One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Platinum Hall of Fame
doi : 10.1016/j.eururo.2023.03.018
Volume 83, Issue 5, May 2023, Pages e121-e131
Systematic Biopsies as a Complement to Magnetic Resonance Imaging–targeted Biopsies: “To Be or Not To Be�?
Johan Stranne a,b,*, Nicolas Mottet c , Olivier Rouvie`re d , on behalf of the EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines Panel
doi : 10.1016/j.eururo.2023.01.012
Volume 83, Issue 5, May 2023, Pages 381-384
Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy–like Picture
Hannah Scha ̈fer a,* ,y, Sarah Mayr a,y, Maike Bu ̈ttner-Herold b , Karina Knorr c , Lisa Steinhelfer c , Carsten A. Bo ̈ger d,e,f , Ju ̈rgen E. Gschwend g , Uwe Heemann a , Matthias Eiber c,à , Christoph Schmaderer a,à , Robert Tauber
doi : 10.1016/j.eururo.2022.05.025
Volume 83, Issue 5, May 2023, Pages 385-390
Better Late than Never for Late Toxicity Assessment
Sai Duriseti a,b , Gholam R. Berenji c,d , Nicholas G. Nickols a,b , Matthew B. Rettig
doi : 10.1016/j.eururo.2023.02.010
Volume 83, Issue 5, May 2023, Pages 391-392
Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries
Steven MacLennan a,*, Nuno Azevedo b , Eilidh Duncan c , Jennifer Dunsmore a , Louise Fullwood d , Nicolaas Lumen e , Karin Plass f , Maria J. Ribal f,g , Monique J. Roobol h , Daan Nieboer h , Natasha Schouten f , Ted A. Skolarus i,j , Emma Jane Smith f , James N’Dow a , Nicolas Mottet f,k , Alberto Briganti l , on behalf of the Pan-European National Urological Society IMAGINE Collaborative (see Supplemental material for group members affiliations):
doi : 10.1016/j.eururo.2022.12.031
Volume 83, Issue 5, May 2023, Pages 393-401
Evidence-practice gaps exist in urology. We previously surveyed European Association of Urology (EAU) guidelines for strong recommendations underpinned by high-certainty evidence that impact patient experience for which practice variations were suspected.
The Long and Winding Road from Guideline Recommendations to Improved Quality of Care
Ola Bratt
doi : 10.1016/j.eururo.2023.01.011
Volume 83, Issue 5, May 2023, Pages 402-404
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISEÂ V2)
Robert Seifert a,*, Louise Emmett b , Steven P. Rowe c,d , Ken Herrmann a,e , Boris Hadaschik f , Jeremie Calais e , Frederik L. Giesel g , Robert Reiter h , Tobias Maurer i,j , Matthias Heck k,l , Andrei Gafita e,Ã , Michael J. Morris m , Stefano Fanti n , Wolfgang A. Weber o , Thomas A. Hope p , Michael S. Hofman q,r , Wolfgang Peter Fendler a,s,y, Matthias Eiber
doi : 10.1016/j.eururo.2023.02.002
Volume 83, Issue 5, May 2023, Pages 405-412
Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) is emerging to become a reference imaging tool for the staging and restaging of patients with prostate cancer for both clinical routine and trials.
A Novel Three-dimensional Planning Tool for Selective Clamping During Partial Nephrectomy: Validation of a Perfusion Zone Algorithm
Pieter De Backer a,b,c,d,*,y, Saar Vermijs b,c,e,y, Charles Van Praet a,c , Pieter De Visschere f , Sarah Vandenbulcke b , Angelo Mottaran d,g,h , Carlo A. Bravi d,h,i , Camille Berquin a , Edward Lambert a , Ste �phanie Dautricourt a , Wouter Goedertier a , Alexandre Mottrie d,h , Charlotte Debbaut b,e,à , Karel Decaestecker
doi : 10.1016/j.eururo.2023.01.003
Volume 83, Issue 5, May 2023, Pages 413-421
Selective clamping during robot-assisted partial nephrectomy (RAPN) requires extensive knowledge on patient-specific renal vasculature, obtained through imaging.
Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study
Sylvia H.J. Jochems a,*, Josef Fritz b , Christel Ha ̈ggstro ̈m c,d , Bengt Ja ̈rvholm e , Pa ̈r Stattin d , Tanja Stocks
doi : 10.1016/j.eururo.2022.03.033
Volume 83, Issue 5, May 2023, Pages 422-431
Prospective and detailed investigations of smoking and prostate cancer (PCa) risk and death are lacking.
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score
Matthew D. Galsky a,*, Dean F. Bajorin b , Johannes Alfred Witjes c , Ju ̈rgen E. Gschwend d , Yoshihiko Tomita e , Federico Nasroulah f , Jun Li f , Sandra Collette g , Begon ̃a P. Valderrama h , Marc-Oliver Grimm i , Leonard Appleman j , Gwenaelle Gravis k , Andrea Necchi l,y, Dingwei Ye m , Frank Stenner n , Megan Wind-Rotolo f,à , Joshua Zhang f , Keziban U ̈nsal-Kac ̧ maz
doi : 10.1016/j.eururo.2023.01.016
Volume 83, Issue 5, May 2023, Pages 432-440
The CheckMate 274 trial demonstrated improved disease-free survival (DFS) with adjuvant nivolumab versus placebo in patients with muscle-invasive urothelial carcinoma at high risk of recurrence after radical surgery in both the intent-to-treat population and the subset with tumor programmed death ligand 1 (PD-L1) expression ≥1%.
Single-cell Deconvolution of a Specific Malignant Cell Population as a Poor Prognostic Biomarker in Low-risk Clear Cell Renal Cell Carcinoma Patients
Judikael R. Saout a , Gwendoline Lecuyer a , Simon Le �onard a,b,c , Bertrand Evrard a , Sole`ne-Florence Kammerer-Jacquet a,d , Laurence Noe ̈l a , Zine-Eddine Khene d , Romain Mathieu a,e , Ange �lique Brunot f , Antoine D. Rolland a , Karim Bensalah e , Nathalie Rioux-Leclercq a,d,1, Aure �lie Lardenois a,1, Fre �de �ric Chalmel
doi : 10.1016/j.eururo.2023.02.008
Volume 83, Issue 5, May 2023, Pages 441-451
Intratumor heterogeneity (ITH) is a key feature in clear cell renal cell carcinomas (ccRCCs) that impacts outcomes such as aggressiveness, response to treatments, or recurrence.
Genetic Architecture of Azoospermia—Time to Advance the Standard of Care
Margot J. Wyrwoll a,y, Nils Ko ̈ckerling a,y, Matthias Vockel b , Ann-Kristin Dicke a , Nadja Rotte a , Eva Pohl a , Jana Emich a , Marius Wo ̈ste c , Christian Ruckert b , Rebecca Wabschke a , Jochen Seggewiss b , Susanne Ledig b , Ann-Christin Tewes b , Yvonne Stratis b , Jann F. Cremers d , Joachim Wistuba d , Claudia Krallmann d , Sabine Kliesch d , Albrecht Ro ̈pke b , Birgit Stallmeyer a , Corinna Friedrich a,à , Frank Tu ̈ttelmann
doi : 10.1016/j.eururo.2022.05.011
Volume 83, Issue 5, May 2023, Pages 452-462
Crypto- and azoospermia (very few/no sperm in the semen) are main contributors to male factor infertility. Genetic causes for spermatogenic failure (SPGF) include Klinefelter syndrome and Y-chromosomal azoospermia factor microdeletions, and CFTR mutations for obstructive azoospermia (OA).
Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy
Michael S. Leapman a,b,* ,1, Cassandra L. Thiel c,d,e,1, Ilyssa O. Gordon f , Adam C. Nolte g , Aaron Perecman h , Stacy Loeb i,j,k , Michael Overcash l , Jodi D. Sherman
doi : 10.1016/j.eururo.2022.12.008
Volume 83, Issue 5, May 2023, Pages 463-471
Reducing low-value clinical care is an important strategy to mitigate environmental pollution caused by health care.
Re: Percentage Gleason Pattern 4 and PI-RADS Score Predict Upgrading in Biopsy Grade Group 2 Prostate Cancer Patients Without Cribriform Pattern
Eva Compérat * André Oszwald Gabriel Wasinger
doi : 10.1016/j.eururo.2023.01.007
Volume 83, Issue 5, May 2023, Page 472
Re: Prostate Cancer Polygenic Risk Score and Prediction of Lethal Prostate Cancer
Sabine D. Brookman-May a,b,* Matthias May
doi : 10.1016/j.eururo.2023.01.006
Volume 83, Issue 5, May 2023, Pages 473-474
Re: Population-based Randomized Trial of Screening for Clinically Significant Prostate Cancer ProScreen: A Pilot Study
Muhieddine Labban a,* Quoc-Dien Trinh a Anthony V. D’Amico
doi : 10.1016/j.eururo.2022.12.028
Volume 83, Issue 5, May 2023, Page 474
Re: The Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy (NRG Oncology/RTOG 0534 SPPORT): An International, Multicentre, Randomised Phase 3 Trial
Mario Terlizzi * Alberto Bossi
doi : 10.1016/j.eururo.2022.12.026
Volume 83, Issue 5, May 2023, Page 475
Re: Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial
Zine-Eddine Khene a Delphine Borchiellini b Karim Bensalah
doi : 10.1016/j.eururo.2022.12.025
Volume 83, Issue 5, May 2023, Pages 475-476
Re: A Randomized Trial of PHOTOdynamic Surgery in Non–muscle-invasive Bladder Cancer
Mario de Angelis * Alberto Briganti Francesco Montorsi Marco Moschini
doi : 10.1016/j.eururo.2023.02.001
Volume 83, Issue 5, May 2023, Pages 477-478
First Ever Radical Prostatectomy Performed with the New Dexter Robotic Systemâ„¢
Dominik Bo ̈hlen *, Rolf Gerber
doi : 10.1016/j.eururo.2023.02.004
Volume 83, Issue 5, May 2023, Pages 479-480
Re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578–80
Francesco Montorsi Simone Scuderi * Alberto Briganti Giorgio Gandaglia
doi : 10.1016/j.eururo.2022.12.038
Volume 83, Issue 5, May 2023, Page e132
Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia’s Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578–80
Melline G.M. Schilham a,b,c,* Mark Rijpkema a Tom Scheenen a Rick Hermsen d Jelle O. Barentsz a J.P.Michiel Sedelaar b,c Heidi Kusters-Vandevelde e Linda G.W. Kerkmeijer f Diederik M. Somford b,g Martin Gotthardt
doi : 10.1016/j.eururo.2023.01.023
Volume 83, Issue 5, May 2023, Pages e133-e134
Re: Ithaar H. Derweesh, Rana R. McKay, Aditya Bagrodia. Primary Cytoreductive Nephrectomy: Standing the Test of Time? Eur Urol. 2023;83:152–3
Arnaud Mejean
doi : 10.1016/j.eururo.2022.12.039
Volume 83, Issue 5, May 2023, Page e135
Re: Kerrington Powell, Michael C. Burns, Vinay Prasad. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint. Eur Urol. 2023;83:101–2
Francesco Montorsi Simone Scuderi * Alberto Briganti Giorgio Gandaglia
doi : 10.1016/j.eururo.2023.01.025
Volume 83, Issue 5, May 2023, Page e136
Re: Sigrid V. Carlsson, Rebecka Arnsrud Godtman, Carl-Gustav Pihl, et al. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial. Eur Urol. 2023;83:103–9
Ki Min Kim a Jae Heon Kim a,* Benjamin I. Chung
doi : 10.1016/j.eururo.2022.12.037
Volume 83, Issue 5, May 2023, Pages e137-e138
Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen–radioguided Surgery. Eur Urol 2022;83:62–9
André Pontes-Silva
doi : 10.1016/j.eururo.2023.01.029
Volume 83, Issue 5, May 2023, Page e139
Erratum to “European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel� [Eur. Urol. 79(4) (2021) 480–488]
Richard J. Sylvester a,*, Oscar Rodrı �guez b , Virginia Herna �ndez a,c , Diana Turturica d , Lenka Bauerova � e , Harman Max Bruins a,f , Johannes Bru ̈ndl g , Theo H. van der Kwast h , Antonin Brisuda i , Jose � Rubio-Briones j , Maximilian Seles k , Anouk E. Hentschel l,m , Venkata R.M. Kusuma n , Nicolai Huebner o , Juliette Cotte p , Laura S. Mertens m , Dimitrios Volanis q , Olivier Cussenot q , Jose D. Subiela Henrı �quez b , Enrique de la Pen ̃a c , Francesca Pisano b,d , Michael Pesˇl s , Antoine G. van der Heijden f , Sonja Herdegen g , Alexandre R. Zlotta t , Jaromir Hacek u , Ana Calatrava v , Sebastian Mannweiler w , Judith Bosschieter l , David Ashabere n , Andrea Haitel x , Jean-Franc ̧ ois Coˆte � y , Soha El Sheikh z , Luca Lunelli r , Ferran Algaba aa , Isabel Alemany bb , Francesco Soria d , Willemien Runneboom cc , Johannes Breyer g , Jakko A. Nieuwenhuijzen l , Carlos Llorente c , Luca Molinaro dd , Christina A. Hulsbergen-van de Kaa cc , Matthias Evert ee , Lambertus A.L.M. Kiemeney ff , James N’Dow gg , Karin Plass gg , Otakar Cˇapoun a,s , Viktor Soukup a,s , Jose L. Dominguez-Escrig a,j , Daniel Cohen a,q , Joan Palou a,b , Paolo Gontero a,d , Maximilian Burger a,g , Richard Zigeuner a,k , Amir Hugh Mostafid a,n , Shahrokh F. Shariat a,i,o , Morgan Roupreˆt a,p , Eva M. Compe �rat a,hh , Marko Babjuk a,i,o , Bas W.G. van Rhijn
doi : 10.1016/j.eururo.2023.02.007
Volume 83, Issue 5, May 2023, Pages e140-e141
